(Q36035236)

11 August 2017

1 reference

title

Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations (English)

1 reference

11 August 2017

myocardial infarction

1 reference

Benjamin J Epstein

1

1 reference

PubMed ID

15701766

11 August 2017

John G Gums

series ordinal

2

1 reference

PubMed ID

15701766

11 August 2017

language of work or name

English

0 references

publication date

8 February 2005

1 reference

Annals of Pharmacotherapy

11 August 2017

1 reference

11 August 2017

39

1 reference

11 August 2017

3

1 reference

11 August 2017

470-480

1 reference

Actual Causes of Death in the United States, 2000

11 August 2017

1 reference

National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction

21 January 2018

1 reference

Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?

21 January 2018

1 reference

ACE-inhibition and angiotensin II receptor blockers in chronic heart failure: pathophysiological consideration of the unresolved battle

21 January 2018

1 reference

21 January 2018

1 reference

The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms

21 January 2018

1 reference

Angiotensin II and the pathophysiology of cardiovascular remodeling

21 January 2018

1 reference

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

21 January 2018

1 reference

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group

21 January 2018

1 reference

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

21 January 2018

1 reference

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?

21 January 2018

1 reference

The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus

21 January 2018

1 reference

Neurohormonal modulation in cardiovascular disease

21 January 2018

1 reference

Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury

21 January 2018

1 reference

Cardiovascular effects of intrathecally administered bradykinin in the rat: characterization of receptors with antagonists

21 January 2018

1 reference

Effects of bradykinin B2 receptor antagonism on the hypotensive effects of ACE inhibition

21 January 2018

1 reference

ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time

21 January 2018

1 reference

Beneficial effects of bradykinin on myocardial energy metabolism and infarct size

21 January 2018

1 reference

Interactions between the renin-angiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease

21 January 2018

1 reference

Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic subst

21 January 2018

1 reference

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

21 January 2018

1 reference

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

21 January 2018

1 reference

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality

21 January 2018

1 reference

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators

21 January 2018

1 reference

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

21 January 2018

1 reference

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

21 January 2018

1 reference

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

21 January 2018

1 reference

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

21 January 2018

1 reference

Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes

21 January 2018

1 reference

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

21 January 2018

1 reference

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party

21 January 2018

1 reference

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

21 January 2018

1 reference

Kidney disease as a risk factor for recurrent cardiovascular disease and mortality

21 January 2018

1 reference

Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients

21 January 2018

1 reference

Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies

21 January 2018

1 reference

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy

21 January 2018

1 reference

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy

21 January 2018

1 reference

Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on postprandial endothelial function

21 January 2018

1 reference

ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1E478

1 reference

11 August 2017

1 reference

PubMed ID

15701766